Crossmark Global Holdings Inc. Boosts Position in Glaukos Co. (NYSE:GKOS)

Crossmark Global Holdings Inc. increased its stake in Glaukos Co. (NYSE:GKOS) by 15.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,051 shares of the medical instruments supplier’s stock after buying an additional 554 shares during the period. Crossmark Global Holdings Inc.’s holdings in Glaukos were worth $527,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in GKOS. Vanguard Group Inc. grew its holdings in Glaukos by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 5,308,897 shares of the medical instruments supplier’s stock worth $500,576,000 after acquiring an additional 72,159 shares in the last quarter. Fred Alger Management LLC grew its holdings in Glaukos by 3.8% during the 2nd quarter. Fred Alger Management LLC now owns 1,278,723 shares of the medical instruments supplier’s stock worth $151,337,000 after acquiring an additional 47,308 shares in the last quarter. Primecap Management Co. CA grew its holdings in Glaukos by 43.9% during the 2nd quarter. Primecap Management Co. CA now owns 1,220,815 shares of the medical instruments supplier’s stock worth $144,483,000 after acquiring an additional 372,180 shares in the last quarter. Driehaus Capital Management LLC grew its holdings in Glaukos by 24.0% during the 2nd quarter. Driehaus Capital Management LLC now owns 803,650 shares of the medical instruments supplier’s stock worth $95,112,000 after acquiring an additional 155,653 shares in the last quarter. Finally, Point72 Asset Management L.P. bought a new position in Glaukos during the 2nd quarter worth about $67,460,000. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Glaukos Stock Performance

GKOS opened at $138.44 on Friday. Glaukos Co. has a 12-month low of $59.22 and a 12-month high of $145.84. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $7.63 billion, a PE ratio of -45.84 and a beta of 1.02. The firm has a 50 day moving average of $130.92 and a two-hundred day moving average of $122.40.

Glaukos (NYSE:GKOS) last posted its quarterly earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.20. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. The company had revenue of $96.70 million during the quarter, compared to analyst estimates of $91.50 million. During the same period last year, the firm posted ($0.50) EPS. Glaukos’s revenue for the quarter was up 23.9% compared to the same quarter last year. On average, analysts anticipate that Glaukos Co. will post -1.96 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have issued reports on GKOS shares. BTIG Research increased their target price on shares of Glaukos from $131.00 to $139.00 and gave the stock a “buy” rating in a report on Wednesday, August 28th. Stifel Nicolaus raised their price target on shares of Glaukos from $130.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. StockNews.com upgraded shares of Glaukos from a “sell” rating to a “hold” rating in a report on Monday, October 21st. Wells Fargo & Company raised their price target on shares of Glaukos from $135.00 to $145.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Finally, Truist Financial raised their price target on shares of Glaukos from $145.00 to $152.00 and gave the company a “buy” rating in a report on Monday, October 14th. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $134.55.

Insiders Place Their Bets

In other news, Director Gilbert H. Kliman sold 3,000 shares of Glaukos stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $130.67, for a total transaction of $392,010.00. Following the completion of the transaction, the director now directly owns 32,336 shares of the company’s stock, valued at $4,225,345.12. The trade was a 8.49 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Joseph E. Gilliam sold 2,275 shares of Glaukos stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total transaction of $316,156.75. Following the transaction, the chief operating officer now directly owns 102,169 shares of the company’s stock, valued at approximately $14,198,425.93. This trade represents a 2.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 10,275 shares of company stock valued at $1,354,967. 6.40% of the stock is owned by insiders.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.